Onconetix (ONCO) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Onconetix, Inc. has appointed Dr. Thomas Meier to its board of directors, leveraging his extensive background as a life-science entrepreneur and executive in the healthcare industry. With a notable career including leadership roles in multiple pharmaceutical and biotech companies, Dr. Meier brings valuable experience to Onconetix’s board. His term is set to last until the 2025 annual meeting, and he will also provide consulting services to the company, with agreed-upon compensation for his expertise. Dr. Meier’s involvement is anticipated to greatly benefit Onconetix, given his international recognition in clinical research, particularly in the field of orphan diseases.
For further insights into ONCO stock, check out TipRanks’ Stock Analysis page.
